UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 ORor 15(d)

of ~~The~~the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 25, 2026

~~Recursion~~RECURSION ~~Pharmaceuticals~~PHARMACEUTICALS, ~~Inc~~INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40323

46-4099738

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

41 S Rio Grande Street

Salt Lake City, UT 84101

(Address of principal executive offices) (Zip code)

(385) 269 - 0203

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (~~17CFR~~17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.~~14d~~13e-24(bc))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Class A Common Stock, par value $0.00001 per share	RXRX	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02. ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~February~~ March 25, 2026, Recursion Pharmaceuticals, Inc. (the “Company”) ~~issued~~announced athat ~~press~~Vicki ~~release~~Goodman, ~~announcing~~M.D., ~~its~~will ~~results~~become ofRecursion’s ~~operations~~Chief ~~and~~Medical ~~financial~~Officer ~~condition~~effective ~~for~~April ~~the~~6, ~~fourth~~2026, ~~quarter~~as ~~and~~David ~~fiscal~~Mauro, ~~year ended December 31~~M.D., ~~2025~~Ph.D. Atransitions ~~copy~~out of the ~~press~~role. ~~release~~In isconnection ~~furnished~~with ashis ~~Exhibit~~departure, 99Dr.1 ~~and~~Mauro iswill ~~incorporated~~continue ~~herein~~to byserve ~~reference~~the Company in an advisory capacity for a transitional period until May 29, 2026.

Item 7.01. Regulation FD Disclosure.

On ~~February 25,~~March ~~2026, February~~ 25, 2026, the Company ~~released~~issued a ~~presentation~~press ~~made~~release inannouncing ~~connection~~the ~~with~~CMO ~~its~~transition ~~L(earnings)~~described ~~call~~in onItem ~~February 25, 2026~~5.02. A copy of the ~~presentation~~press release is attached hereto as Exhibit 99.21.

The ~~Company announces material~~ information tofurnished ~~its~~in ~~investors~~this ~~using~~Item ~~filings~~7.01 ~~with~~(including ~~the~~Exhibit ~~Securities~~99.1), ~~and~~shall ~~Exchange~~not ~~Commission~~be ~~(the~~deemed “~~SEC~~filed”), ~~the~~for ~~investor~~purposes ~~relations~~of ~~page~~Section on18 of the ~~Company’s~~Securities ~~website,~~Exchange atAct ~~https://ir.recursion.com/,~~of ~~press releases~~1934, ~~public~~as ~~conference~~amended ~~calls~~(the ~~and~~“Exchange ~~webcasts. The Company uses these channels~~Act”), asor ~~well~~otherwise assubject ~~social media,~~ to ~~communicate with investors and~~ the ~~public~~liabilities ~~about~~of ~~the~~that ~~Company~~section, ~~its~~nor ~~products~~shall ~~and~~it ~~services~~be ~~and~~deemed ~~other~~incorporated ~~matters.~~by ~~Therefore,~~reference ~~the~~in ~~Company~~any ~~encourages~~filing ~~investors,~~under the ~~media~~Securities ~~and~~Act ~~others~~of ~~interested~~1933, inas ~~the~~amended, ~~Company~~or ~~to review~~ the ~~information~~Exchange ~~it makes public in these locations~~Act, except as ~~such~~expressly ~~information~~set ~~could~~forth beby ~~deemed~~specific toreference bein ~~material~~such ~~information~~filing.

The information furnished pursuant to Item 2.02 (including Exhibit 99.1) and 7.01 (including Exhibit 99.2) on this Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number			Description
99.1			Press ~~release~~Release ~~issued~~of by Recursion Pharmaceuticals, Inc. dated ~~February~~March 25, 2026.
99.2			L(earnings) call presentation of Recursion Pharmaceuticals, Inc. dated February 25, 2026
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned ~~thereunto~~hereunto duly authorized on ~~February~~March 25, 2026.

RECURSION PHARMACEUTICALS, INC. By: /s/ ~~Ben~~Nathan ~~Taylor~~Hatfield ~~Ben~~Nathan ~~Taylor~~Hatfield Chief ~~Financial~~Legal Officer

Filing Compare · RECURSION PHARMACEUTICALS, INC.